www.fdanews.com/articles/137153-novartis-8217-canakinumab-shows-benefits-in-two-phase-iii-gouty-arthritis-studies
Novartis’ Canakinumab Shows Benefits in Two Phase III Gouty Arthritis Studies
May 27, 2011
Novartis reported positive data from two Phase III studies evaluating its fully human monoclonal antibody canakinumab (ACZ885) in the treatment of severe gouty arthritis. The combined data showed that in comparison with treatment using the injectable steroid triamcinolone acetonide (TA), therapy using subcutaneously injected canakinumab provided better pain relief and reduced the risk of new attacks by up to 68 percent.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News